8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Feb 17, 2026·SEC
Material company update
Jan 12, 2026·SEC
Krystal Biotech, Inc.(KRYS)Earnings, Financials & Key Ratios
KRYS•NASDAQ
50.9× P/E·Price updated Jun 19, 2026
AboutKrystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.Show more
- Revenue$389M+33.9%
- EBITDA$168M+131.8%
- Net Income$205M+129.7%
- EPS (Diluted)6.84+128.0%
- Gross Margin92.61%-0.5%
- EBITDA Margin43.13%+73.1%
- Operating Margin41.45%+83.3%
- Net Margin52.64%+71.5%
- ROE18.91%+83.0%
KRYS Key Insights
Krystal Biotech, Inc. (KRYS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓FCF machine: 48.5% free cash flow margin
- ✓Momentum leader: RS Rating 89 (top 11%)
- ✓Healthy 5Y average net margin of 35.0%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when KRYS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KRYS Price & Volume
Krystal Biotech, Inc. (KRYS) stock price & volume — 10-year historical chart
Loading chart...
KRYS Growth Metrics
Krystal Biotech, Inc. (KRYS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM25.15%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM81.53%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM79.81%
Return on Capital
10 Years-14.89%
5 Years-7.06%
3 Years1.88%
Last Year14.77%
KRYS Recent Earnings
Krystal Biotech, Inc. (KRYS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (45%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$1.83+26.2%
$1.45
Rev
$116M+3.8%
$112M
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$1.70+4.9%
$1.62
Rev
$107M+1.7%
$105M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$2.66+137.5%
$1.12
Rev
$98M-7.1%
$105M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$1.29+19.4%
$1.08
Rev
$96M+0.7%
$95M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $1.83vs $1.45+26.2% | $116Mvs $112M+3.8% |
| Q1 2026 | Feb 17, 2026 | $1.70vs $1.62+4.9% | $107Mvs $105M+1.7% |
| Q4 2025 | Nov 3, 2025 | $2.66vs $1.12+137.5% | $98Mvs $105M-7.1% |
| Q3 2025 | Aug 4, 2025 | $1.29vs $1.08+19.4% | $96Mvs $95M+0.7% |
Based on last 12 quarters of dataView full earnings history →
KRYS Peer Comparison
Krystal Biotech, Inc. (KRYS) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 |
Compare KRYS vs Peers
Krystal Biotech, Inc. (KRYS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KRYS Income Statement
Krystal Biotech, Inc. (KRYS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 1.03M | 0 | 0 | 0 | 0 | 50.7M | 290.51M | 389.13M | 417.3M |
Revenue Growth % | - | - | -100% | - | - | - | - | 473.02% | 33.94% | 25.15% |
Cost of Goods Sold | 23K | 141K | 974K | 1.85M | 0 | 0 | 3.09M | 20.06M | 28.77M | 30.07M |
COGS % of Revenue | - | 13.73% | - | - | - | - | 6.1% | 6.91% | 7.39% | - |
Gross Profit | -23K▲ 0% | 886K▲ 3952.2% | -974K▼ 209.9% | -1.85M▼ 90.0% | 0▲ 100.0% | 0▲ 0% | 47.6M▲ 0% | 270.45M▲ 468.1% | 360.36M▲ 33.2% | 387.24M▲ 0% |
Gross Margin % | - | 86.27% | - | - | - | - | 93.9% | 93.09% | 92.61% | 92.79% |
Gross Profit Growth % | -1050% | 3952.17% | -209.93% | -90.04% | 100% | - | - | 468.12% | 33.24% | - |
Operating Expenses | 4.77M | 11.92M | 22.08M | 31.15M | 68.28M | 145.2M | 157.33M | 204.76M | 199.06M | 208.43M |
OpEx % of Revenue | - | 1160.27% | - | - | - | - | 310.33% | 70.48% | 51.16% | - |
Selling, General & Admin | 1.56M | 4.16M | 6.46M | 13.21M | 40.39M | 77.73M | 98.4M | 113.69M | 146.74M | 155.03M |
SG&A % of Revenue | - | 404.58% | - | - | - | - | 194.09% | 39.13% | 37.71% | - |
Research & Development | 3.21M | 7.76M | 15.62M | 17.94M | 27.88M | 42.46M | 46.43M | 53.57M | 58.05M | 59.12M |
R&D % of Revenue | - | 755.7% | - | - | - | - | 91.58% | 18.44% | 14.92% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 25M | 12.5M | 37.5M | -5.72M | -1000K |
Operating Income | -4.77M▲ 0% | -11.92M▼ 149.7% | -22.08M▼ 85.3% | -33M▼ 49.4% | -68.28M▼ 106.9% | -145.2M▼ 112.7% | -109.73M▲ 24.4% | 65.69M▲ 159.9% | 161.29M▲ 145.5% | 178.81M▲ 0% |
Operating Margin % | - | -1160.27% | - | - | - | - | -216.43% | 22.61% | 41.45% | 42.85% |
Operating Income Growth % | -317.5% | -149.71% | -85.31% | -49.45% | -106.9% | -112.66% | 24.43% | 159.87% | 145.52% | - |
EBITDA | -4.75M | -11.78M | -21.11M | -31.15M | -66.43M | -141.81M | -103.82M | 72.41M | 167.85M | 185.45M |
EBITDA Margin % | - | -1146.54% | - | - | - | - | -204.77% | 24.92% | 43.13% | 44.44% |
EBITDA Growth % | -316.21% | -147.95% | -79.25% | -47.57% | -113.26% | -113.49% | 26.79% | 169.75% | 131.8% | 60.85% |
D&A (Non-Cash Add-back) | 23K | 141K | 974K | 1.85M | 1.85M | 3.38M | 5.91M | 6.71M | 6.55M | 6.64M |
EBIT | -4.66M | -10.89M | -19.09M | -32.17M | -68.08M | -120.2M | -97.23M | 103.19M | 161.29M | 178.81M |
Net Interest Income | 0 | 0 | 2.99M | 832K | -1.29M | 5.22M | 22.62M | 29.66M | 28.18M | 0 |
Interest Income | 0 | 0 | 2.99M | 832K | 197K | 5.22M | 22.62M | 29.66M | 28.18M | 0 |
Interest Expense | 3.15M | 1.03M | 0 | 0 | 1.49M | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -3.15M | 1.03M | 2.99M | 832K | -1.29M | 5.22M | 122.62M | 29.66M | 28.18M | 28.51M |
Pretax Income | -7.92M▲ 0% | -10.89M▼ 37.5% | -19.09M▼ 75.3% | -32.17M▼ 68.5% | -69.57M▼ 116.3% | -139.97M▼ 101.2% | 12.9M▲ 109.2% | 95.36M▲ 639.4% | 189.47M▲ 98.7% | 207.32M▲ 0% |
Pretax Margin % | - | -1060.27% | - | - | - | - | 25.44% | 32.82% | 48.69% | 49.68% |
Income Tax | 0 | -20.14K | 0 | 0 | 0 | 0 | 1.97M | 6.2M | -15.36M | -17.71M |
Effective Tax Rate % | 0% | 0.18% | 0% | 0% | 0% | 0% | 15.24% | 6.5% | -8.11% | -8.54% |
Net Income | -7.92M▲ 0% | -10.89M▼ 37.5% | -19.09M▼ 75.3% | -32.17M▼ 68.5% | -69.57M▼ 116.3% | -139.97M▼ 101.2% | 10.93M▲ 107.8% | 89.16M▲ 715.6% | 204.83M▲ 129.7% | 225.03M▲ 0% |
Net Margin % | - | -1060.27% | - | - | - | - | 21.56% | 30.69% | 52.64% | 53.92% |
Net Income Growth % | -588.7% | -37.49% | -75.3% | -68.52% | -116.28% | -101.2% | 107.81% | 715.58% | 129.74% | 81.53% |
Net Income (Continuing) | -7.92M | -10.89M | -19.09M | -32.17M | -69.57M | -139.97M | 10.93M | 89.16M | 204.83M | 225.03M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.48▲ 0% | -0.97▲ 34.5% | -1.20▼ 23.7% | -1.71▼ 42.5% | -3.13▼ 83.0% | -5.49▼ 75.4% | 0.39▲ 107.1% | 3.00▲ 669.2% | 6.84▲ 128.0% | 7.38▲ 0% |
EPS Growth % | -448.15% | 34.46% | -23.71% | -42.5% | -83.04% | -75.4% | 107.1% | 669.23% | 128% | 79.81% |
EPS (Basic) | -1.48 | -0.97 | -1.20 | -1.71 | -3.13 | -5.49 | 0.40 | 3.12 | 7.08 | - |
Diluted Shares Outstanding | 5.36M | 11.2M | 15.9M | 18.79M | 22.2M | 25.49M | 27.75M | 29.74M | 29.95M | 30.51M |
Basic Shares Outstanding | 5.36M | 11.2M | 15.9M | 18.79M | 22.2M | 25.49M | 27.15M | 28.59M | 28.94M | 29.29M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
KRYS Balance Sheet
Krystal Biotech, Inc. (KRYS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 49.91M | 112.65M | 195.88M | 275.06M | 442.27M | 383.78M | 587.91M | 742.04M | 1.02B | 1.02B |
Cash & Short-Term Investments | 49.59M | 111.76M | 193.69M | 271.26M | 438.1M | 379.17M | 532.18M | 597.52M | 827.79M | 823.4M |
Cash Only | 49.59M | 103.67M | 187.51M | 268.27M | 341.25M | 161.9M | 358.33M | 344.87M | 496.3M | 501.31M |
Short-Term Investments | 0 | 8.09M | 6.17M | 2.99M | 96.85M | 217.27M | 173.85M | 252.65M | 331.49M | 322.09M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 42.04M | 104.75M | 127.42M | 127.02M |
Days Sales Outstanding | - | - | - | - | - | - | 302.66 | 131.6 | 119.52 | 108.35 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 6.99M | 26.51M | 40.48M | 42.65M |
Days Inventory Outstanding | - | - | - | - | - | - | 824.02 | 482.3 | 513.45 | 460.66 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 4.61M | 6.71M | 13.27M | 28.91M | 26.67M |
Total Non-Current Assets | 200K | 3.47M | 13.14M | 35.79M | 184.03M | 174.67M | 230.45M | 313.79M | 309.19M | 377.23M |
Property, Plant & Equipment | 200K | 3.01M | 11.18M | 34.17M | 119.58M | 169.73M | 168.23M | 161.45M | 158.01M | 160.62M |
Fixed Asset Turnover | - | 0.34x | - | - | - | - | 0.30x | 1.80x | 2.46x | 2.64x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 497K | 0 | 64.37M | 4.62M | 61.95M | 152.11M | 128.07M | 593.47M |
Other Non-Current Assets | 0 | 452K | 1.46M | 1.61M | 74K | 324K | 263K | 231K | 287K | 300K |
Total Assets | 50.11M▲ 0% | 116.12M▲ 131.7% | 209.02M▲ 80.0% | 310.84M▲ 48.7% | 626.29M▲ 101.5% | 558.45M▼ 10.8% | 818.36M▲ 46.5% | 1.06B▲ 29.0% | 1.33B▲ 26.3% | 1.4B▲ 0% |
Asset Turnover | - | 0.01x | - | - | - | - | 0.06x | 0.28x | 0.29x | 0.33x |
Asset Growth % | 2196.7% | 131.7% | 80.01% | 48.71% | 101.48% | -10.83% | 46.54% | 29.02% | 26.33% | 106.64% |
Total Current Liabilities | 640K | 2.6M | 3.33M | 15.45M | 25.74M | 28.85M | 33.09M | 102M | 102.94M | 107.8M |
Accounts Payable | 193K | 888K | 1.02M | 2.1M | 8.4M | 3.98M | 1.85M | 4.99M | 3.24M | 4.09M |
Days Payables Outstanding | 3.06K | 2.3K | 382.61 | 415.09 | - | - | 218.13 | 90.7 | 41.08 | 50.22 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.8M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 437K | 1.36M | 12K | 26K | 87K | 267K | 16.75M | 2.4M | 97.93M | 101.91M |
Current Ratio | 77.99x | 43.39x | 58.88x | 17.80x | 17.18x | 13.30x | 17.76x | 7.28x | 9.95x | 9.46x |
Quick Ratio | 77.99x | 43.39x | 58.88x | 17.80x | 17.18x | 13.30x | 17.55x | 7.02x | 9.56x | 9.06x |
Cash Conversion Cycle | - | - | - | - | - | - | 908.56 | 523.2 | 591.89 | 518.8 |
Total Non-Current Liabilities | 0 | 294K | 2.78M | 3.31M | 6.98M | 7.37M | 6.62M | 7.46M | 11.29M | 12.44M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 2.78M | 3.31M | 6.98M | 7.37M | 6.62M | 6.04M | 7.57M | 23.45M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 294K | 0 | 0 | 0 | 0 | 0 | 1.42M | 3.72M | 12.44M |
Total Liabilities | 640K | 2.89M | 6.11M | 18.76M | 32.72M | 36.22M | 39.71M | 109.46M | 114.23M | 120.24M |
Total Debt | 0 | 0 | 3.26M | 11.55M | 8.02M | 8.93M | 8.09M | 7.26M | 9.34M | 1.8M |
Net Debt | -49.59M | -103.67M | -184.25M | -256.72M | -333.22M | -152.97M | -350.23M | -337.6M | -486.96M | -499.51M |
Debt / Equity | - | - | 0.02x | 0.04x | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | 0.10x | 0.06x | 0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -4.66x | -2.90x | -2.69x |
Interest Coverage | -1.48x | -10.60x | - | - | -45.63x | - | - | - | - | - |
Total Equity | 49.47M▲ 0% | 113.23M▲ 128.9% | 202.91M▲ 79.2% | 292.08M▲ 43.9% | 593.58M▲ 103.2% | 522.23M▼ 12.0% | 778.64M▲ 49.1% | 946.38M▲ 21.5% | 1.22B▲ 28.9% | 1.28B▲ 0% |
Equity Growth % | 17019.03% | 128.86% | 79.21% | 43.94% | 103.22% | -12.02% | 49.1% | 21.54% | 28.87% | 111.03% |
Book Value per Share | 9.23 | 10.11 | 12.76 | 15.55 | 26.74 | 20.49 | 28.06 | 31.82 | 40.72 | 41.85 |
Total Shareholders' Equity | 49.47M | 113.23M | 202.91M | 292.08M | 593.58M | 522.23M | 778.64M | 946.38M | 1.22B | 1.28B |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -9.07M | -19.96M | -39.05M | -71.21M | -140.78M | -280.76M | -269.83M | -180.67M | 24.16M | 80.09M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -25K | 2K | 10K | 6K | -163K | -728K | 638K | -190K | 1.14M | -1.62M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KRYS Cash Flow Statement
Krystal Biotech, Inc. (KRYS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.89M | -9.45M | -18.71M | -26.08M | -47.94M | -100.57M | -88.8M | 123.42M | 200.87M | 250.28M |
Operating CF Margin % | - | -919.67% | - | - | - | - | -175.16% | 42.48% | 51.62% | - |
Operating CF Growth % | -196.72% | -142.8% | -98.13% | -39.38% | -83.79% | -109.79% | 11.7% | 238.98% | 62.75% | 1538.71% |
Net Income | -7.92M | -10.89M | -19.09M | -32.17M | -69.57M | -139.97M | 10.93M | 89.16M | 204.83M | 225.03M |
Depreciation & Amortization | 23K | 141K | 748K | 1.85M | 2.77M | 4.05M | 5.01M | 6.71M | 6.55M | 6.44M |
Stock-Based Compensation | 246K | 792K | 1.24M | 3.27M | 15.32M | 33.23M | 39.93M | 49.13M | 54.51M | 27.73M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -22.84M | -22.84M |
Other Non-Cash Items | 3.26M | 962K | 67K | 33K | 1.49M | -690K | -106.79M | -7.12M | -5.77M | 17.8M |
Working Capital Changes | 498K | 511K | -1.68M | 928K | 2.05M | 2.81M | -37.88M | -14.46M | -36.42M | -3.87M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | -42.04M | -62.71M | -22.12M | -23.55M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -4.47M | -11.91M | -6.29M | -5.13M |
Change in Payables | 133K | 112K | -199K | 783K | 712K | -1.25M | -101K | 1.01M | 826K | 942K |
Cash from Investing | -210K | -10.32M | -4.97M | -11.18M | -226.77M | -114.08M | 82.64M | -163.44M | -58.42M | -67.23M |
Capital Expenditures | -210K | -2.23M | -6.4M | -14.84M | -68.34M | -52.98M | -11.8M | -4.24M | -11.95M | -12.89M |
CapEx % of Revenue | - | 217.53% | - | - | - | - | 23.27% | 1.46% | 3.07% | 3.09% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 435K | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 100M | 0 | 0 | 0 |
Cash from Financing | 51.77M | 73.85M | 107.53M | 118.02M | 347.69M | 35.35M | 202.75M | 27.01M | 8.71M | 10.71M |
Debt Issued (Net) | 2.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 49.47M | 73.85M | 107.53M | 118.02M | 355.64M | 36M | 203.5M | 32.4M | 22.66M | 10.74M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -16.96M |
Other Financing | 0 | 0 | 0 | 0 | -7.96M | -649K | -749K | -5.39M | -13.96M | -28K |
Net Change in Cash | 47.67M▲ 0% | 54.08M▲ 13.4% | 83.84M▲ 55.0% | 80.75M▼ 3.7% | 72.98M▼ 9.6% | -179.35M▼ 345.8% | 196.43M▲ 209.5% | -13.46M▼ 106.9% | 151.44M▲ 1224.9% | 192.54M▲ 0% |
Free Cash Flow | -4.1M▲ 0% | -11.68M▼ 184.9% | -25.11M▼ 115.0% | -40.93M▼ 63.0% | -116.27M▼ 184.1% | -153.55M▼ 32.1% | -100.6M▲ 34.5% | 119.18M▲ 218.5% | 188.91M▲ 58.5% | 237.38M▲ 0% |
FCF Margin % | - | -1137.2% | - | - | - | - | -198.43% | 41.02% | 48.55% | 56.88% |
FCF Growth % | -209.2% | -184.85% | -115.02% | -62.97% | -184.11% | -32.06% | 34.48% | 218.47% | 58.51% | 83.56% |
FCF per Share | -0.76 | -1.04 | -1.58 | -2.18 | -5.24 | -6.02 | -3.63 | 4.01 | 6.31 | 7.78 |
FCF Conversion (FCF/Net Income) | 0.49x | 0.87x | 0.98x | 0.81x | 0.69x | 0.72x | -8.12x | 1.38x | 0.98x | 1.05x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.67M | 0 | 13.48M |
KRYS Key Ratios
Krystal Biotech, Inc. (KRYS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -31.83% | -13.39% | -12.08% | -13% | -15.71% | -25.09% | 1.68% | 10.34% | 18.91% | 19.25% |
Return on Invested Capital (ROIC) | -7780.43% | -189.36% | -117.38% | -91.62% | -34.63% | -34.59% | -20.63% | 9.5% | 18.04% | 18.12% |
Gross Margin | - | 86.27% | - | - | - | - | 93.9% | 93.09% | 92.61% | 92.79% |
Net Margin | - | -1060.27% | - | - | - | - | 21.56% | 30.69% | 52.64% | 53.92% |
Debt / Equity | - | - | 0.02x | 0.04x | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x | 0.00x |
Interest Coverage | -1.48x | -10.60x | - | - | -45.63x | - | - | - | - | - |
FCF Conversion | 0.49x | 0.87x | 0.98x | 0.81x | 0.69x | 0.72x | -8.12x | 1.38x | 0.98x | 1.05x |
Revenue Growth | - | - | -100% | - | - | - | - | 473.02% | 33.94% | 25.15% |
Related:KRYS Dividend History·KRYS Revenue History·KRYS Price History·KRYS P/E History·KRYS Financial Ratios·KRYS Institutional Holders
KRYS SEC Filings & Documents
Krystal Biotech, Inc. (KRYS) SEC filings — annual & quarterly reports (10-K, 10-Q)
KRYS Frequently Asked Questions
Krystal Biotech, Inc. (KRYS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Krystal Biotech, Inc. (KRYS) reported $417.3M in revenue for fiscal year 2025.
Krystal Biotech, Inc. (KRYS) grew revenue by 33.9% over the past year. This is strong growth.
Yes, Krystal Biotech, Inc. (KRYS) is profitable, generating $225.0M in net income for fiscal year 2025 (52.6% net margin).
Dividend & Returns
Krystal Biotech, Inc. (KRYS) has a return on equity (ROE) of 18.9%. This is reasonable for most industries.
Krystal Biotech, Inc. (KRYS) generated $237.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.